Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
| 1.79 | |
| 1.79 | |
| - | |
| 1.79 | |
| 1.79 | |
| 0.16-3.78 | |
| 2 761 K | |
| 1 542 K | |
| 0 | |
| -4.2762 | |
| 1.965 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
NEW YORK, Feb. 25, 2023 (GLOBE NEWSWIRE) -- First Miami Bancorp, Inc. (OTC: FMIA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale ...
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston filed the first class action lawsuit against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) and aga...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
